The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The researchers are aimed to investigate the early diagnosis of pulmonary nodule based on DNA, RNA, protein, metabolites through analyzing the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and clinical characteristics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

NCT07047573

Lung Cancer (Diagnosis) Pulmonary Nodule Persistent

RECRUITING

Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

NCT03181490

Pulmonary Nodule, Solitary

COMPLETED

Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath

NCT06518655

Pulmonary Nodules, Multiple Pulmonary Nodules, Solitary Lung Cancer

RECRUITING

SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules

NCT06775587

Lung Cancer in Normal and Malignant Tumors

NOT_YET_RECRUITING

Breath Combined With CT for Diagnoses of Pulmonary Nodules

NCT04948047

Non-small Cell Lung Cancer Pulmonary Nodule, Multiple

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

By recruiting people with pulmonary nodules identified by CT scans, three groups are confirmed as the lung cancer group, the benign lung nodule group who are identified by pathological analysis, and the small lung nodule group that should be followed up. Then the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Nodule, Solitary Lung; Node

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lung cancer

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.

Intervention Type DIAGNOSTIC_TEST

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

benign lung nodule

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.

Intervention Type DIAGNOSTIC_TEST

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

lung nodule

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.

Intervention Type DIAGNOSTIC_TEST

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For lung cancer groups

* (1) Patients diagnosed with lung cancer;
* (2) Clear diagnosis by pathological examination to determine pathological type;
* (3) Those aged 18-80 years old;
* (4) For patients with newly diagnosed lung cancer, CT confirmed that the size of primary lung cancer is ≤ 3 cm;
* (5) The patient or family member agrees to participate in the study and sign an informed consent form;
* (6) No other serious cardiopulmonary diseases. For lung nodule
* (1) Those aged 18-80 years;
* (2) CT clear lung nodule size ≤ 3cm;
* (3) 1-3cm pulmonary nodules confirmed by pathological diagnosis as non-lung cancer or other metastatic cancer patients or ≤1cm pulmonary nodules
* (4) The patient or family member agrees to participate in the study and sign an informed consent form;
* (5) No other serious cardiopulmonary diseases.

Exclusion Criteria

* (1) Women who are breast-feeding, pregnant or preparing for pregnancy;
* (2) Those who are allergic to allergies and multiple drugs;
* (3) Combining severe primary diseases such as cardiovascular and cerebrovascular, liver, kidney, and hematopoietic system, as well as subjects with mental illness;
* (4) concurrently infected;
* (5) Those who participated in other clinical trials within three months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes